Gut-Brain Axis in Ageing with Proper Citation

1. Introduction to the Gut-Brain Axis and Ageing

1.1 Overview of Gut-Brain Axis (GBA)

The gut-brain axis (GBA) refers to a complex, bidirectional communication network that links the central nervous system (CNS) with the gastrointestinal tract, primarily through the gut microbiota. This intricate system involves multiple pathways, including neural, immune, endocrine, and metabolic interactions. The neural pathways are chiefly mediated through the vagus nerve and enteric nervous system, providing rapid signaling between the gut and brain. The immune system conveys information via cytokine release and immune cell activation, while endocrine influences include hormone secretion, and metabolic pathways involve microbial metabolites acting as signaling molecules. The gut microbiota, comprising trillions of microorganisms such as bacteria, viruses, fungi, and archaea, plays a pivotal role in modulating this axis by producing metabolites and neuroactive compounds that influence brain function and behavior. In the context of ageing, the GBA is particularly significant as alterations in this communication can profoundly affect cognitive function and overall brain health. Dysregulation in the GBA has been implicated in various neurological conditions and cognitive decline associated with ageing. Understanding the fundamental mechanisms of this axis is crucial for developing interventions aimed at preserving brain health in the elderly. Recent research underscores the essential nature of the microbiota-gut-brain axis in maintaining homeostasis and mediating physiological processes throughout the lifespan (Khan, 2024). Complementing this, extensive reviews have detailed the integral role of gut microorganisms in CNS disorders, illustrating that disruptions in gut microbiota composition and function can lead to neurological consequences (Cryan, 2019). Moreover, the molecular interactions within this bidirectional system, including microbial metabolites and immune signaling, reinforce the concept of the gut-brain network’s systemic influence (Kanmani, 2020).

1.2 Significance of Ageing in Gut-Brain Axis Research

Ageing represents a multifaceted biological process that entails systemic physiological changes impacting various organ systems, including both the gut and the brain. One of the critical areas of interest is how ageing modulates the gut microbiota composition, which in turn exerts influence over neurodegenerative processes. Alterations in the microbiota—commonly referred to as dysbiosis—during ageing are characterized by reduced microbial diversity, loss of beneficial taxa, and increased pro-inflammatory bacteria. This microbial imbalance is linked with an increased systemic inflammatory state described as “inflammaging,” a chronic low-grade inflammation that exacerbates neuronal vulnerability and cognitive decline. The interplay between ageing, inflammation, and the microbiota is a vital area of research as it offers mechanistic insights into age-related neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. The concept of inflammaging bridges the immune and metabolic changes occurring with age and highlights the relevance of modulating gut microbiota to attenuate neuroinflammatory pathways. Importantly, recent works emphasize that while chronological ageing is inevitable, biological ageing rates vary significantly among individuals depending on microbiome stability and environmental factors, pointing towards the gut microbiota as a modifiable determinant of brain ageing outcomes (Sarubbo, 2023). Furthermore, ageing-associated low-grade inflammation has a multifactorial origin, with gut microbiota-immune axis alterations playing a central role in sustaining this inflammatory milieu and contributing to age-related disease pathogenesis (Calder, 2017). The relationship between the microbiota and ageing is also underscored by emergent evidence supporting microbiota’s impact on brain function regulation and behavior modulation, which is particularly pertinent in the context of cognitive ageing and neurodegeneration (Boehme, 2022).

1.3 Objectives and Scope of Review

This review aims to integrate and synthesize the current body of evidence regarding the gut-brain axis in the context of ageing, with a particular focus on the molecular, cellular, and metabolic changes of the gut microbiota that influence brain function during this process. The scope includes critical examination of alterations in microbiota composition that accompany ageing and how these changes affect microbial metabolite profiles, immune interactions, and neurochemical signaling pathways. Furthermore, the review explores therapeutic potentials aimed at correcting dysbiosis or enhancing protective microbial functions to support cognitive health in elderly populations. It also evaluates the most recent advances in therapeutic strategies such as probiotics, prebiotics, synbiotics, and dietary modulation. Particular attention is given to elucidating mechanisms whereby microbial metabolites and immune pathways interface with brain ageing, neuroinflammation, and neurodegenerative diseases. An encompassing perspective is provided, drawing from preclinical and clinical findings, to propose effective strategies for leveraging the gut microbiota for neuroprotection and cognitive resilience (Loh, 2024). Additionally, the review considers emerging clinical interventions and their underpinning mechanistic rationales, offering insight into future directions for research and therapeutic development (Bicknell, 2023). The importance of balancing ecological microbiome factors to regulate neurotrophic factors and suppress inflammatory responses is central to the therapeutic implications discussed herein (Zou, 2024).

2. Changes in Gut Microbiota Composition with Ageing

2.1 Alteration in Microbial Diversity and Abundance

Ageing is frequently accompanied by significant alterations in gut microbial biodiversity and relative abundance of bacterial taxa. Typically, there is a marked reduction in beneficial commensal bacteria such as those belonging to the phylum Bacteroidetes, which are known for their role in maintaining gut barrier function and producing anti-inflammatory metabolites. Concurrently, an expansion of Proteobacteria, a phylum often associated with inflammation and dysbiosis, is commonly observed. This compositional shift contributes to a less resilient and imbalanced microbial ecosystem, termed dysbiosis, which correlates with adverse health outcomes including cognitive deficits. Industrialized nations exemplify the impact of lifestyle factors such as westernized diets characterized by low fiber intake, which exacerbate loss of microbial diversity and beneficial species, underscoring the environmental influence on microbial ageing trajectories. The relationship between reduced microbial diversity and cognitive impairment has been highlighted in several experimental models and human studies, implicating gut microbiota as a determinant factor in brain ageing health (Shi, 2021). Dietary interventions rich in fermentable fibers have demonstrated the capacity to restore some of these microbial imbalances, improving cognitive parameters and neural integrity (Li, 2023). Understanding these compositional changes and their functional consequences is critical for designing microbiota-targeted strategies to prevent or mitigate age-related cognitive decline (Khan, 2024).

2.2 Microbiota-Derived Metabolites and Their Altered Profiles

Microbial metabolites serve as pivotal mediators between the gut microbiota and the brain, influencing CNS function and neuroimmune crosstalk. Among these, short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate, are vital for intestinal epithelial health and systemic immune modulation. Age-related dysbiosis often results in reduced SCFA production, with butyrate—a key neuroprotective molecule—exhibiting decreased levels. Altered production and availability of tryptophan metabolites, particularly those involved in the kynurenine pathway, further modulate neuroinflammatory processes and neurotransmitter balances that affect cognition and mood. The depletion of beneficial microbial metabolites compromises neuroprotection and exacerbates inflammatory cascades. These mechanisms elucidate how changes in metabolite profiles during ageing contribute to brain function alterations and neurodegeneration. Additionally, gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter produced by certain gut bacteria, shows dysregulated levels in ageing-related neurological disorders, underscoring the importance of microbial neuromodulators in maintaining neural homeostasis (ORiordan, 2022). These microbial metabolite imbalances intimate that therapeutic restoration of metabolite production could serve as a viable approach to safeguard cognitive functions during ageing (Silva, 2020). Further, emerging evidence indicates that GABA production by gut microbiota can impact brain function, influencing psychological health and resilience in ageing populations (Braga, 2024).

2.3 Consequences of Dysbiosis on Gut Barrier and Systemic Inflammation

The decline in microbial diversity and the emergence of dysbiotic communities during ageing are linked to impaired gut barrier integrity, leading to increased intestinal permeability—a condition often termed “leaky gut.” This dysfunction facilitates translocation of bacterial endotoxins such as lipopolysaccharides (LPS) into systemic circulation, provoking chronic low-grade systemic inflammation, commonly referred to as inflammaging. This persistent inflammatory state serves as a driving factor for neuroinflammation, contributing to neural damage and cognitive deficits in aged populations. The compromised intestinal barrier integrity also disrupts homeostatic immune crosstalk between the gut and brain, exacerbating neurodegenerative pathways. Studies in animal models have validated these findings, demonstrating that dysbiosis-induced barrier dysfunction correlates with exacerbations in neuropathology and cognitive performance declines. The close interplay between gut permeability, systemic inflammation, and CNS inflammation highlights the gut barrier as a critical interface in brain ageing and a potential therapeutic intervention point (Mou, 2022). Correspondingly, nutritional and microbiome-modulating strategies aiming to restore barrier function show promise in attenuating inflammatory cascades that underlie neurodegeneration in ageing (Calder, 2017). Notably, dietary fiber deficiency has been experimentally shown to impair intestinal barrier and reduce SCFA production, reinforcing the importance of microbiota-mediated barrier maintenance in cognitive health (Shi, 2021).

3. Molecular and Cellular Mechanisms Linking Gut Microbiota and Brain Ageing

3.1 Role of Microbial Metabolites in Neuroimmune Modulation

Microbial metabolites intricately regulate neuroimmune functions and consequently influence brain ageing processes. SCFAs, chiefly butyrate, act as critical modulators of microglial maturation and functionality within the CNS, promoting anti-inflammatory phenotypes, and maintaining immune homeostasis. Moreover, metabolites produced through the tryptophan-kynurenine pathway modulate both excitatory and inhibitory neurotransmitter systems and affect neuroinflammatory responses. Dysregulated kynurenine metabolism due to altered microbiota can lead to the accumulation of neurotoxic intermediates, exacerbating neuronal injury. Similarly, bacterial amyloids and elevated LPS levels resulting from dysbiotic microbiota provoke activation of microglia and astrocytes, triggering neuroinflammatory cascades implicated in the progression of neurodegenerative diseases. These pathogen-associated molecular patterns (PAMPs) contribute to chronic neuroinflammation in ageing brains. The complex interplay of microbial metabolites and immunomodulation underscores their central roles in bridging peripheral gut signals to CNS aging pathology (Zou, 2024). Complementing this, studies have elucidated that microbial amyloids can exacerbate amyloidogenic processes in the brain, adding a dimension to microbiota’s influence on neurodegeneration (Pistollato, 2016). Additionally, the modulation of blood-brain barrier permeability by microbial metabolites facilitates immune cell trafficking and inflammatory mediator infiltration into the CNS, further potentiating degenerative cascades (Mou, 2022).

3.2 Neurotransmitters and Neuroactive Compounds of Microbial Origin

Beyond metabolites, gut microbiota produce a variety of neuroactive compounds that directly or indirectly influence brain function. Gamma-aminobutyric acid (GABA), one of the primary inhibitory neurotransmitters in the CNS, is synthesized by certain gut bacteria and can modulate central inhibitory signaling, impacting mood, anxiety, and cognitive functions. Altered levels of GABA-producing microorganisms and correlated fluctuations in brain and circulating GABA have been linked to neuropsychiatric conditions, which often co-occur with ageing-related cognitive decline. Similarly, neuropeptides belonging to the neuropeptide Y (NPY) family, including peptide YY (PYY) and pancreatic polypeptide (PP), are expressed both centrally and peripherally with significant roles in gastrointestinal motility, energy balance, stress resilience, and mood regulation. These neuropeptides have been shown to interact with the gut microbiota and immune system, forming an additional layer in gut-brain communication. Furthermore, gut microbiota influence the synthesis and metabolism of monoamines, such as serotonin, a neurotransmitter fundamental for mood regulation and cognitive processing. Alterations in microbial communities thus can disrupt serotonergic signaling with potential downstream effects on brain ageing and mental health. This array of neuroactive compounds constitutes a critical interface, highlighting the direct biochemical influence of the microbiota on CNS aging and neuropsychiatric vulnerabilities (Braga, 2024). The modulation of neuropeptide Y systems has been linked to reductions in anxiety and depression-related behaviors, emphasizing their therapeutic relevance in ageing populations (Holzer, 2012). Moreover, microbiota-driven effects on serotonin synthesis provide a biochemical substrate for microbiome influence on mood and cognition (Jenkins, 2016).

3.3 Impact on Blood-Brain Barrier and Neural Plasticity

The integrity of the blood-brain barrier (BBB) is essential for preserving CNS homeostasis and shielding the brain from peripheral insults. Ageing-associated microbiota dysbiosis can induce BBB permeability alterations, allowing increased passage of systemic inflammatory mediators and microbial products into the brain parenchyma. This breach facilitates neuroinflammatory activation, contributing to impaired synaptic function, neuronal loss, and reduced plasticity observed in ageing and neurodegenerative conditions. Microbial metabolites, particularly SCFAs, can positively influence synaptic integrity and hippocampal neuroplasticity, preserving cognitive functions. However, diminished SCFA levels due to dysbiosis compromise these protective effects. Experimental evidence indicates that microglial activation triggered by microbial dysbiosis affects synaptic pruning processes, further impairing cognitive abilities. Taken together, these mechanisms align gut microbial changes with key neurodegenerative features in ageing brains, suggesting that microbiota-targeted interventions may preserve BBB function and support synaptic resilience (Shi, 2021). In parallel, investigations into mechanisms regulating microglial function by microbiota underscore their importance for maintaining brain homeostasis and counteracting neurodegeneration (Loh, 2024). Moreover, dietary or probiotic interventions that restore beneficial microbiota have shown promise in enhancing neurotrophic factors and BBB integrity (Li, 2023).

4. Nutritional Influences on the Gut-Brain Axis during Ageing

4.1 Dietary Fiber and Microbiota-Mediated Effects

Dietary fiber acts as a fundamental substrate for gut microbiota fermentation into beneficial metabolites such as SCFAs. Long-term fiber-deficient diets induce significant shifts in microbiota composition, marked by loss of beneficial taxa and increased abundance of potentially pathogenic bacteria. Animal models simulating human-like fiber deficiency replicate cognitive impairments, including deficits in memory and executive function. Mechanistically, fiber deficiency hampers SCFA production, undermines intestinal barrier integrity, and accelerates hippocampal synaptic loss through microglial activation and neuroinflammation. These findings implicate dietary fiber as a critical modulator of the microbiota-hippocampal axis and cognitive aging trajectories. The protective roles of fiber intake against age-related cognitive decline are thus gaining traction as modifiable lifestyle factors (Shi, 2021). Supporting this, SCFAs derived from fiber fermentation exert neuromodulatory and anti-inflammatory effects in the CNS, reinforcing the importance of maintaining adequate fiber consumption for microbiota homeostasis and brain health (Silva, 2020). This nutritional influence aligns with polyphenol-rich diets and other interventions targeting gut-brain communication to mitigate functional losses during ageing (Sarubbo, 2023).

4.2 Polyphenols as Modulators of Gut Microbiota and Brain Health

Polyphenols, bioactive compounds abundant in plant-based foods, possess antioxidant and anti-inflammatory properties that have a profound impact on both gut microbiota composition and brain ageing. These compounds modulate the gut microbiota by promoting the growth of beneficial microbes and enhancing their metabolic activity, including SCFA production. The consumption of polyphenols correlates with improved gut barrier function, reduced systemic and neuroinflammation, and better cognitive performance in ageing models. Experimental and preclinical data suggest that polyphenols positively influence neuroplasticity, neurotrophic factor expression, and oxidative stress parameters in the brain. However, while mechanistic insights are becoming clearer, well-designed human clinical trials remain limited, underscoring the need to establish dietary polyphenols as effective strategies against brain ageing (Sarubbo, 2023). Additionally, expanded dietary polyphenol studies reveal their role in the modulation of microbial metabolites, further linking their intake to the preservation of cognitive functions (Lng, 2024). Theaflavins present in black tea exemplify such bioactive compounds, demonstrating neuroprotective capabilities through microbiota and metabolite remodeling (Li, 2023).

4.3 Other Dietary Components Affecting Gut-Brain Axis

Beyond polyphenols and fiber, other dietary components significantly impact the gut-brain axis during ageing. Theaflavins, enzymatic oxidation products of catechins in black tea, have demonstrated remarkable effects in mitigating cognitive dysfunction in ageing models. These compounds contribute to gut homeostasis by enhancing antioxidant capabilities, modulating immune responses, and restoring tight junction protein expression, thereby strengthening gut barrier integrity. The resultant restructuring of the gut microbiota and increased SCFA and amino acid metabolite levels correlate positively with behavioral improvements, highlighting dietary theaflavins as promising neuroprotective agents (Li, 2023). Additionally, nutrients such as omega-3 fatty acids and vitamin D exhibit modulatory effects on inflammatory pathways and gut microbial communities, further supporting cognitive health. Their anti-inflammatory and immunomodulatory properties complement microbiota-targeted interventions and reinforce the significance of a balanced diet in maintaining microbial homeostasis and healthy ageing (Calder, 2017). Collectively, these dietary factors substantiate the essential role of nutrition in shaping the microbiota-gut-brain axis and preserving neurological function.

5. Probiotic and Prebiotic Interventions in Ageing-Associated Cognitive Decline

5.1 Effects of Probiotics on Gut Microbiota Composition and Inflammation

Probiotic supplementation, involving live beneficial bacteria, offers a compelling strategy to modulate gut microbiota composition and attenuate age-related inflammation, thereby supporting cognitive health. Multi-strain probiotic formulations such as ProBiotic-4, containing various Bifidobacterium and Lactobacillus species, have been shown to improve memory and reduce neuroinflammation in ageing mouse models. These probiotics enhance intestinal and blood-brain barrier integrity, lower systemic endotoxin levels, and downregulate pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha. Molecular analyses reveal that probiotics inhibit key inflammatory pathways such as the Toll-like receptor 4 (TLR4) and nuclear factor-kappa B (NF-κB) signaling axes, mitigating neuroinflammatory cascades. The attenuation of microglial activation and restoration of synaptic protein expression further corroborate the neuroprotective effects of probiotics in ageing contexts. These findings emphasize the therapeutic potential of probiotics in rebalancing gut microbial ecosystems to counter cognitive decline (Yang, 2019). Moreover, probiotics also influence systemic immune function and exhibit capacity to restore microbial diversity, supporting their role within multisystem aging (Kanmani, 2020). The protective roles of probiotics in maintaining cognitive function align with observations linking microbiota dysbiosis to brain ageing (Shi, 2021).

5.2 Prebiotics and Synbiotics in Supporting Cognitive Function

Prebiotics, non-digestible dietary fibers that selectively stimulate the growth of beneficial microbes, complement probiotics in promoting a healthy gut environment. Through fostering the expansion of commensal bacteria, prebiotics facilitate increased production of SCFAs and other metabolites critical for neuroprotection and the maintenance of gut barrier integrity. When combined with probiotics, as synbiotics, synergistic effects emerge, enhancing microbial diversity, immune modulation, and metabolic function more effectively than either intervention alone. Experimental studies have shown that such synbiotic interventions improve cognitive performance and reduce neurodegenerative markers in ageing models. Prebiotic supplementation also positively modulates inflammation and oxidative stress within the CNS, thereby reinforcing neuronal resilience. These promising outcomes support the development of combined microbiome-targeted interventions as viable strategies to preserve cognition during ageing (Zou, 2024). In addition, clinical perspectives underscore synbiotics' capacity for slowing dementia progression and improving quality of life in neurodegenerative diseases, further encouraging translational applications (Bicknell, 2023). Prebiotics and synbiotics also display efficacy in modulating gut-brain immune pathways, aligning with therapeutic approaches in age-associated brain disorders (Zhu, 2020).

5.3 Fecal Microbiota Transplantation and Emerging Therapies

Fecal microbiota transplantation (FMT), involving the transfer of healthy donor microbiota to re-establish a balanced gut environment, has emerged as a potential therapeutic modality for neurodegenerative diseases characterized by dysbiosis. FMT aims to restore microbial diversity, reduce systemic inflammation, and rebalance microbial metabolite profiles, mitigating pathological features of ageing-related neurological disorders. However, clinical translation faces challenges, including safety concerns, donor selection criteria, and variability of outcomes. In parallel, novel therapeutic techniques such as photobiomodulation targeting the microbiota-gut-brain axis are being explored to modulate microbial populations and inflammatory responses non-invasively. While preclinical findings are promising, extensive clinical trials assessing efficacy, optimal protocols, and long-term safety are necessary before routine application. The integration of FMT and emerging therapies within multi-modal treatment regimens could revolutionize managing cognitive decline and neurodegeneration in ageing populations (Bicknell, 2023). Furthermore, mechanistic insights underline the necessity of targeting multiple microbiota-host pathways to optimize therapeutic benefit (Loh, 2024). These interventions represent a frontier in personalized medicine approaches for ageing brain health (Zhu, 2020).

6. Gut-Brain Axis Dysregulation in Alzheimer's Disease and Other Neurodegenerative Disorders

6.1 Microbiota Alterations and Amyloid Pathology in Alzheimer's Disease

Alzheimer’s disease (AD), a leading cause of dementia, is increasingly understood as a disorder influenced by gut microbiota dysregulation. Alterations in microbial diversity and function contribute to the pathogenesis of AD by promoting amyloid-beta (Aβ) aggregation, tau pathology, and neuroinflammation. Bacterial amyloids and LPS emanating from dysbiotic gut microbiota activate microglia, inducing chronic neuroinflammation that exacerbates amyloid and tau-mediated neurotoxicity. These microbial factors mimic host amyloidogenic processes through molecular mimicry, enhancing protein misfolding and propagation in the brain. Therapeutically, strategies aimed at rebalancing gut microbiota to suppress inflammation and upregulate neurotrophic factors show promise in modifying disease progression. Modulation of the gut microbial ecological balance, therefore, emerges as a viable intervention point in AD management and prevention. Recent reviews emphasize the necessity of investigating microbiota-centric treatments, including prebiotics, probiotics, synbiotics, and FMT, as complementary approaches alongside conventional AD therapies (Zou, 2024). The potential of targeting gut microbiota is further supported by data demonstrating a correlation between dysbiosis and clinical disease markers in AD patients (Zhu, 2020). Moreover, understanding the microbiota’s contribution to AD neuropathology provides novel insights into disease mechanisms and expands therapeutic horizons (Kowalski, 2019).

6.2 Parkinson's Disease and Gut Microenvironmental Changes

Parkinson’s disease (PD), another major neurodegenerative disorder, is characterized by alpha-synuclein aggregation and dopaminergic neuronal loss. Mounting evidence suggests that gut microenvironmental alterations, including microbiota dysbiosis and chronic gut inflammation, precede and contribute to PD pathology. The bidirectional communication along the gut-brain axis mediates spread of pathological alpha-synuclein from enteric neurons to the central nervous system. Dysregulated immune responses, impaired intestinal barrier integrity, and altered microbial metabolites promote systemic and neuroinflammation, aggravating neurodegeneration in genetically susceptible individuals. The complex interplay between genetic predispositions and environmental triggers, notably gut microbiota alterations, underscores the multifaceted etiology of PD. Therapeutic approaches focused on normalizing the gut microenvironment and microbial composition offer potential to modify disease progression. Investigations into microbial metabolites and immune pathways are elucidating key mechanisms for intervention (Chen, 2022). Furthermore, the microbiota-gut-brain axis provides a framework to comprehend clinical heterogeneity and progression patterns in PD (Loh, 2024). Clinical correlation between microbial ecology and PD symptomatology reinforces gut-targeted therapeutic prospects (Zhu, 2020).

6.3 Other Neurodegenerative and Neurodevelopmental Conditions

Beyond AD and PD, the gut-brain axis is implicated in various other neurodegenerative and neurodevelopmental disorders such as multiple sclerosis, autism spectrum disorder (ASD), and attention-deficit hyperactivity disorder (ADHD). Dysbiosis and altered metabolite signaling contribute to immune dysregulation, neuroinflammation, and neural circuit dysfunction characteristic of these conditions. The gut microbiota composition offers potential biomarkers for early diagnosis and disease progression monitoring. Moreover, microbiota modulation strategies may offer therapeutic avenues across a spectrum of neurological diseases. Establishing common and disease-specific microbiota signatures aids in understanding disease mechanisms and facilitates personalized treatment approaches. The broad role of the gut-brain axis across neurological disorders substantiates the microbiome as a critical factor in brain health and disease (Bicknell, 2023). Preclinical and clinical data indicate that interventions targeting microbial dysbiosis can ameliorate symptoms and alter disease trajectories in neurodevelopmental and neurodegenerative spectrums (Loh, 2024). Additionally, the gut-brain axis offers a conceptual model linking metabolic, inflammatory, and neurochemical pathways in these diverse disorders (Khan, 2024).

7. Immune and Inflammatory Pathways in the Gut-Brain Axis during Ageing

7.1 Inflammaging and Chronic Low-Grade Inflammation

The phenomenon of inflammaging describes the chronic, low-grade systemic inflammation characteristic of ageing, driven in part by alterations in the gut microbiota and associated immune dysregulation. Microbiota-induced inflammatory states perpetuate immune activation both peripherally and within the CNS, contributing to neuroinflammatory processes that impair neuronal function and cognition. Persistent mucosal immune dysregulation promotes intestinal barrier dysfunction and endotoxin leakage, fueling systemic inflammatory cascades. The sustained inflammatory environment compromises neuronal integrity and accelerates neurodegenerative changes, forming a pathological nexus between inflammaging and cognitive decline. Dietary, microbiota-targeted, and pharmacologic interventions seek to mitigate this inflammatory burden to preserve brain health with ageing (Calder, 2017). The intricate crosstalk between gut-derived cytokines and CNS immune responses further defines this inflammatory axis (Mou, 2022). Therapeutic modulation of microbial populations and their products holds promise to attenuate inflammaging and its detrimental sequelae (Zou, 2024).

7.2 Toll-Like Receptors and Immune Signaling

Toll-like receptors (TLRs) serve as pivotal pattern recognition receptors within innate immunity, detecting microbial components such as LPS and bacterial amyloids. Among them, TLR4 and retinoic acid-inducible gene I (RIG-I) pathways are especially relevant in mediating neuroimmune activation and regulating blood-brain barrier permeability. In ageing and dysbiosis contexts, overactivation of TLRs leads to exacerbated neuroinflammation, microglial activation, and BBB disruption, thereby accelerating neurodegenerative processes. Notably, probiotic treatments have demonstrated efficacy in modulating TLR signaling, reducing inflammatory cytokine production and restoring barrier function. Inhibiting NF-κB translocation downstream of TLR activation is a key mechanism whereby microbial-targeted therapies achieve neuroprotection. Integrative approaches targeting TLR-mediated pathways offer promising avenues to counteract neuroinflammation associated with brain ageing and cognitive decline (Yang, 2019). The centrality of TLRs in gut-brain immune signaling highlights their potential as biomarkers and therapeutic targets in microbiota-mediated neurodegeneration (Caputi, 2018). Furthermore, clinical trials emphasize the modulation of immune receptors as a mechanism for probiotics and prebiotics to exert beneficial effects (Loh, 2024).

7.3 Microglial Activation and Neuroimmune Interactions

Microglia, the resident immune cells of the CNS, display dynamic interactions with the gut microbiota that influence their maturation, activation state, and function. Age-related dysbiosis can aberrantly activate microglia, promoting phagocytic engulfment of synapses and neurotoxic factor release that impairs neuronal viability and synaptic function. This microglial dysregulation contributes to synaptic loss and cognitive decline seen in brain ageing and neurodegenerative diseases. Targeting microglial activation through microbiota-directed interventions offers a therapeutic strategy to preserve synaptic integrity and modulate neuroinflammation. Experimental evidence in animal models demonstrates that correcting gut dysbiosis attenuates microglial activation and supports neuroprotection (Shi, 2021). Analysis of microglial communication with other glial cells and neurons further delineates key pathways for immunomodulation in ageing brains (Loh, 2024). Nutritional and probiotic modulation of microglial pathways emerges as a promising frontier in preventing cognitive decline (Zhu, 2020).

8. Neurotransmitter Systems and Neuroendocrine Modulation by the Microbiota

8.1 GABA and Other Inhibitory Neurotransmitters

Gamma-aminobutyric acid (GABA) represents a critical inhibitory neurotransmitter that maintains CNS excitatory-inhibitory balance. Gut microbiota contribute to endogenous pools of GABA via metabolite production, influencing brain levels and hence neuropsychiatric outcomes. Dysregulation of GABAergic signaling is evident in ageing and neurodegenerative conditions, impacting mood, anxiety, and cognitive function. Furthermore, gut-generated GABA may interact with brain homocarnosine pathways, modulating brain function and stress resilience. Probiotics or dietary interventions that induce GABA-producing bacteria present a novel therapeutic approach for mental health disorders prevalent in ageing populations. The emerging elucidation of gut GABA metabolism uncovers significant avenues for microbiota-targeted neurotherapeutics (Braga, 2024). In addition, the modulation of glutamatergic signaling by microbial metabolites further influences excitatory neurotransmission critical for cognitive processes (Baj, 2019). The broad gut-brain influence on neurotransmitters sets a neurochemical framework for microbiome relevance in CNS ageing and disease (Cryan, 2019).

8.2 Neuropeptide Y and Related Peptides

Neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP) form a family of neuropeptides integral to the gut-brain axis, with regulatory roles in gastrointestinal motility, energy homeostasis, stress response, and mood disorders. These peptides are produced at distinct sites along the axis, with differential expression in the digestive system and the CNS. Through specific receptors (Y1, Y2, Y4, Y5), they influence neuroendocrine signaling that modulates anxiety, depression, and stress resilience, all of which are pertinent to ageing brain health. Interaction with the gut microbiota modifies their activity and expression, indicating a complex neuroimmune interplay essential for maintaining homeostasis. These neuropeptides also exhibit anti-inflammatory properties and neuroprotective potential, representing targets for modifying the impact of microbiota dysregulation in ageing (Holzer, 2012). Their role in attenuating anxiety and depression-like behaviors underscores their therapeutic potential within microbiota-gut-brain frameworks (Kanmani, 2020). GABAergic pathways interact with neuropeptide signaling, further integrating neurochemical modulation by microbiota (Braga, 2024).

8.3 Serotonergic and Glutamatergic Pathways

The serotonergic system, originating primarily from the raphe nuclei in the brainstem, is fundamental to mood regulation, cognition, and neuroplasticity. Gut microbes influence peripheral serotonin synthesis, which in turn impacts central serotonergic pathways through multiple mechanisms including modulation of tryptophan availability and metabolism. Altered serotonin signaling is closely linked with ageing-associated mood disorders and cognitive deficits. Moreover, glutamatergic signaling, the main excitatory neurotransmission system, is modulated by microbial metabolites affecting receptor activity involved in stress responses, cognition, and behavioral regulation. Dysregulation of both serotonergic and glutamatergic pathways contributes to neuropsychiatric and neurodegenerative diseases frequently emerging during ageing. Evidence supports the use of probiotics and dietary modifications to restore neurotransmitter balance and alleviate neurofunctional impairments (Jenkins, 2016). Microbiota involvement in neurotransmitter modulation presents an integrative axis influencing brain ageing (Baj, 2019). The complex neurotransmitter crosstalk orchestrated by gut microbiota opens avenues for targeted interventions (Braga, 2024).

9. Limitations, Challenges, and Research Gaps in Current Evidence

9.1 Translational Limitations from Animal to Human Studies

While animal models have significantly advanced understanding of gut-brain interactions during ageing, extrapolation to human populations poses challenges due to interindividual microbiota variability influenced by genetics, lifestyle, environment, and diet. Many human studies remain correlative, lacking mechanistic clarity and causal inference. The complexity of the human microbiome and ethical constraints limit longitudinal and intervention studies, leading to potential biases and confounding. Robust multi-omics and systems biology approaches, combined with large-scale longitudinal cohorts, are needed to bridge these gaps and establish reproducible biomarkers and therapeutic targets. These translational limitations underscore the necessity for carefully designed human clinical trials to validate preclinical findings and refine interventions aimed at microbiota-mediated brain health in ageing (Khan, 2024). Incorporating personalized medicine frameworks responsive to individual microbiome profiles may enhance translational success (Bicknell, 2023). Furthermore, biological ageing markers distinct from chronological age require integration into microbiome research for accurate phenotyping (Boehme, 2022).

9.2 Standardization Issues in Microbiota-Based Interventions

A significant challenge in microbiota-targeted therapies lies in the lack of standardized probiotic strains, dosages, treatment durations, and administration protocols. Variability in these parameters complicates comparison across studies, affecting reproducibility and clinical efficacy. Regulatory oversight and quality control also impact the adoption of microbiota-based therapeutics. Safety profiles and potential adverse effects require thorough investigation, especially in elderly and immunocompromised populations. Overcoming these standardization barriers necessitates coordinated efforts to define clear guidelines, optimize delivery systems, and develop diagnostic tools for monitoring microbiota modulation outcomes. Such advances will facilitate the integration of microbiome-based interventions into clinical practice, ensuring consistency and safety in therapeutic applications for brain ageing (Kanmani, 2020). Rigorous clinical trials evaluating these parameters remain a priority to advance microbiota modulation as a standard of care (Loh, 2024). Moreover, combining probiotic efficacy with mechanistic insights enhances targeted application (Yang, 2019).

9.3 Complexity of Gut-Brain Interactions and Multifactorial Influences

The gut-brain axis embodies a highly complex network influenced by multifactorial elements including host genetics, dietary habits, environmental exposures, medication use, and lifestyle factors. This multifaceted interplay complicates the dissection of causal relationships between microbiota dynamics and brain ageing outcomes. The overlapping signal transduction pathways involving immune modulation, neurotransmitter synthesis, metabolic signaling, and barrier integrity demand integrative systems biology and computational modeling to unravel. Additionally, microbiota compositions are dynamic and fluctuate over time, challenging the identification of stable diagnostic biomarkers. Personalized, longitudinal studies that encompass multi-omic layers—genomics, transcriptomics, metabolomics, and proteomics—are required to capture this complexity. These efforts will elucidate individualized disease mechanisms and foster tailored preventative and therapeutic strategies. Addressing this complexity is critical to realize the full potential of the microbiota-gut-brain axis in promoting brain health and mitigating neurodegeneration during ageing (Barrett, 2017). Understanding the intersecting pathways linking microbiota and the immune chronically inflamed ageing phenotype remains essential for comprehensive insight (Mou, 2022). Continued advancements in data integration platforms will enhance precision in microbiota-targeted therapies (Bicknell, 2023).

10. Conclusions and Future Directions

10.1 Summary of Current Knowledge

The microbiota-gut-brain axis emerges as a vital modulator of brain ageing and neurodegenerative disease pathways. Age-associated dysbiosis and resultant shifts in microbial metabolites profoundly influence neuroinflammation, synaptic plasticity, blood-brain barrier integrity, and cognitive function. Multiple molecular mediators, including SCFAs, tryptophan metabolites, GABA, and neuropeptides, orchestrate gut-to-brain signaling, with significant implications for brain health maintenance. Nutritional modulation, probiotics, prebiotics, and emerging therapies offer promising strategies to harness this axis for neuroprotection. However, the translational gap warrants robust human research to corroborate animal model findings and optimize therapeutic regimens (Khan, 2024). The evolution of microbiota research in brain ageing foreshadows a paradigm shift in preventive and interventional neurology (Sarubbo, 2023). Probiotic administration exemplifies potential clinical applications benefiting cognitive outcomes (Yang, 2019).

10.2 Prospects for Clinical Translation

Clinical translation of gut microbiota modulation encompasses several promising interventions such as polyphenol-enriched diets, probiotic supplementation, prebiotic and synbiotic combinations, and fecal microbiota transplantation. These approaches aim to restore microbial diversity, balance immune responses, and enhance neuroprotective metabolite production, thereby delaying or attenuating cognitive decline in ageing populations. However, implementation hinges on rigorous, controlled human trials to clarify optimal dosing, treatment duration, and long-term safety. Preventative strategies targeting early ageing phases may yield the greatest benefits. Integration of microbiota assessments into clinical evaluations could personalize interventions, maximizing efficacy. The expanding evidence base fuels optimism for gut-targeted therapies to become integral components of ageing brain health management (Li, 2023). Advances in understanding neuroimmune and metabolic underpinnings facilitate rational design of microbiota-based therapeutics (Zou, 2024). Robust translational studies are essential for turning experimental potentials into clinical realities (Bicknell, 2023).

10.3 Recommendations for Future Research

Future investigations should prioritize detailed mechanistic studies focusing on gut-brain communication pathways within human ageing cohorts, employing multi-omics and longitudinal designs to capture dynamic microbiota-host interactions. Standardization in microbiota-targeted therapeutic protocols, including strain selection, dosage regimens, and treatment timing, is critical to ensure reproducibility and clinical application. Integrative systems biology approaches combining genomic, metabolomic, immunologic, and neuroimaging data will clarify complex interactions and facilitate personalized medicine. Broader research is required to elucidate the influence of diet-microbiota-host interplay across the lifespan, establishing preventive nutritional guidelines to maintain brain health. Explorations into less-studied microbial metabolites and novel neuroactive compounds are recommended to expand therapeutic targets. Collaborative, multidisciplinary efforts involving clinicians, microbiologists, neurobiologists, and computational scientists are indispensable to fully exploit gut-brain axis modulation for healthy ageing (Boehme, 2022). Emphasis on immune signaling components within the GBA will further delineate inflammation’s role in neurodegeneration (Loh, 2024). Nutrition-focused interventions warrant deeper exploration for inflammaging control (Calder, 2017).